Vaxcyte trains its sight on a lucrative market with pneumococcal vaccine
Pharmaceutical Technology
OCTOBER 28, 2022
billion and $812 million in 2028. The post Vaxcyte trains its sight on a lucrative market with pneumococcal vaccine appeared first on Pharmaceutical Technology. According to GlobalData, Pharmaceutical Technology’s parent company, Prevnar 13 and Vaxneuvance are forecasted to have global sales of $7.26 Further plans in the making.
Let's personalize your content